Effects of Glucagon on Myocardial Oxygen Consumption and Coronary Blood Flow in Man and in Dog
1970; Lippincott Williams & Wilkins; Volume: 41; Issue: 4 Linguagem: Inglês
10.1161/01.cir.41.4.579
ISSN1524-4539
AutoresJoel H. Manchester, William W. Parmley, Jack M. Matloff, A. JAMES LEIDTKE, Paul J. LaRaia, Michael V. Herman, Edmund H. Sonnenblick, Richard Gorlin,
Tópico(s)Cardiovascular Function and Risk Factors
ResumoHomeCirculationVol. 41, No. 4Effects of Glucagon on Myocardial Oxygen Consumption and Coronary Blood Flow in Man and in Dog Free AccessResearch ArticlePDF/EPUBAboutView PDFSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessResearch ArticlePDF/EPUBEffects of Glucagon on Myocardial Oxygen Consumption and Coronary Blood Flow in Man and in Dog JOEL H. MANCHESTER, M.D., WILLIAM W. PARMLEY, M.D., JACK M. MATLOFF, M.D., A. JAMES LEIDTKE, M.D., PAUL J. LARAIA, M.D., MICHAEL V. HERMAN, M.D., EDMUND H. SONNENBLICK, M.D. and RICHARD GORLIN, M.D. JOEL H. MANCHESTERJOEL H. MANCHESTER , WILLIAM W. PARMLEYWILLIAM W. PARMLEY , JACK M. MATLOFFJACK M. MATLOFF , A. JAMES LEIDTKEA. JAMES LEIDTKE , PAUL J. LARAIAPAUL J. LARAIA , MICHAEL V. HERMANMICHAEL V. HERMAN , EDMUND H. SONNENBLICKEDMUND H. SONNENBLICK and RICHARD GORLINRICHARD GORLIN Originally published1 Apr 1970https://doi.org/10.1161/01.CIR.41.4.579Circulation. 1970;41:579–588AbstractThe effects of intravenous administration of glucagon (50 µg/kg) on left coronary blood flow and myocardial oxygen consumption were studied in nine patients during diagnostic cardiac catheterization and in six open-chested anesthetized dogs. Coronary blood flow was measured with the 133Xe washout technic in man, and with an electromagnetic flowmeter placed around the left anterior descending coronary artery in the dogs. In the patients, glucagon produced a 31% increase in coronary blood flow and a 29% increase in myocardial oxygen consumption, with no change in coronary arteriovenous (A-V) O2 difference across the heart. In the dogs glucagon produced a 114% increase in coronary blood flow and a 131% increase in myocardial oxygen consumption, again with no change in coronary A-V O2 difference. Thus glucagon is a secondary coronary vasodilator in both man and dog. The modest chronotropic and inotropic effects of glucagon observed in man were only half as great as those observed in the dog. Part or all of this difference in dose-response relationship between the two species may be related to the different experimental conditions of the study. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bertero E, Sequeira V, Heymans S and Maack C (2019) Response to 'The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes', European Heart Journal, 10.1093/eurheartj/ehz243, 41:2, (326-327), Online publication date: 7-Jan-2020. Petersen K, Bøgevig S, Holst J, Knop F and Christensen M (2018) Hemodynamic Effects of Glucagon: A Literature Review, The Journal of Clinical Endocrinology & Metabolism, 10.1210/jc.2018-00050, 103:5, (1804-1812), Online publication date: 1-May-2018. Anderson A (2008) Management of Beta-Adrenergic Blocker Poisoning, Clinical Pediatric Emergency Medicine, 10.1016/j.cpem.2007.12.001, 9:1, (4-16), Online publication date: 1-Mar-2008. BIRD S (2007) β-Adrenergic Antagonists Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 10.1016/B978-0-7216-0693-4.50065-7, (975-982), . Murthy D, White C, Katten D, Ahlberg A, Salloum A and Heller G (2000) Effect of Intravenous Metoprolol or Intravenous Metoprolol plus Glucagon on Dobutamine-Induced Myocardial Ischemia, Pharmacotherapy, 10.1592/phco.20.17.1303.34888, 20:11, (1303-1309), Online publication date: 1-Nov-2000. Korvald C, Elvenes O, Ytrebø L, Sørlie D and Myrmel T (1999) Oxygen-wasting effect of inotropy in the "virtual work model", American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.1999.276.4.H1339, 276:4, (H1339-H1345), Online publication date: 1-Apr-1999. Love J and Howell J (1997) Glucagon Therapy in the Treatment of Symptomatic Bradycardia, Annals of Emergency Medicine, 10.1016/S0196-0644(97)70327-5, 29:1, (181-183), Online publication date: 1-Jan-1997. Toet A, Wemer J, Vleeming W, te Biesebeek J, Meulenbelt J and de Wildt D (2016) Experimental study of the detrimental effect of dopamine/glucagon combination in d,l- propranolol intoxication, Human & Experimental Toxicology, 10.1177/096032719601500509, 15:5, (411-421), Online publication date: 1-May-1996. Love J, Leasure J and Mundt D (1993) A comparison of combined amrinone and glucagon therapy to glucagon alone for cardiovascular depression associated with propranolol toxicity in a canine model, The American Journal of Emergency Medicine, 10.1016/0735-6757(93)90168-B, 11:4, (360-363), Online publication date: 1-Jul-1993. Love J, Leasure J, Mundt D and Janz T (2008) A Comparison of Amrinone and Glucagon Therapy for Cardiovascular Depression Associated with Propranolol Toxicity in a Canine Model, Journal of Toxicology: Clinical Toxicology, 10.3109/15563659209021555, 30:3, (399-412), Online publication date: 1-Jan-1992. Peterson C, Leeder J and Sterner S (2016) Glucagon Therapy for β-Blocker Overdose, Drug Intelligence & Clinical Pharmacy, 10.1177/106002808401800507, 18:5, (394-398), Online publication date: 1-May-1984. Wei J, Spotnitz H, Spotnitz W, Benvenisty A, Haasler G, Malm J and Hoffman B (1984) Pharmacologic antagonism of propranolol in dogs, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/S0022-5223(19)38456-9, 87:5, (732-742), Online publication date: 1-May-1984. Farah A (1983) Glucagon and the Heart Glucagon II, 10.1007/978-3-642-69019-8_31, (553-609), . Tarnow J (1983) Pharmakologie und klinische Anwendung kreislaufwirksamer Medikamente Anaesthesie und Kardiologie in der Herzchirurgie, 10.1007/978-3-642-68894-2_3, (163-262), . Rodgers R, MacLeod K and McNeill J (1981) Responses of rat and guinea pig hearts to glucagon. Lack of evidence for a dissociation between changes in myocardial cyclic 3'5'-adenosine monophosphate and contractility., Circulation Research, 49:1, (216-225), Online publication date: 1-Jul-1981. Lefer A and Trachte G (1980) Effects of Hormones on the Heart Hearts and Heart-Like Organs, 10.1016/B978-0-12-119402-4.50007-5, (1-40), . Prasad K and Weckworth P (1978) Glucagon in procainamide-induced cardiac toxicity, Toxicology and Applied Pharmacology, 10.1016/0041-008X(78)90097-2, 46:2, (517-528), Online publication date: 1-Nov-1978. Simaan J and Fawaz G (1976) The cardiodynamic and metabolic effects of glucagon, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/BF00508396, 294:3, (277-283), Online publication date: 1-Sep-1976. Arstila M, Iisalo E, Kallio V, Nousiainen R and Viljanen M (2009) THE EFFECT OF A LONG-ACTING GLUCAGON PREPARATION ON ENDOCRINE AND METABOLIC RESPONSES IN ACUTE MYOCARDIAL INFARCTION, Acta Medica Scandinavica, 10.1111/j.0954-6820.1974.tb01034.x, 196:1-6, (423-430) Shaver J, Lombardo A and Shaver V (1974) Anaerobiosis induced by isoproterenol and glucagon in the presence of restricted coronary inflow, American Heart Journal, 10.1016/0002-8703(74)90396-2, 87:1, (97-104), Online publication date: 1-Jan-1974. LEKVEN J and SEMB G (1974) Effect of Dopamine and Calcium on Lipolysis and Myocardial Ischemic Injury following Acute Coronary Occlusion in the Dog, Circulation Research, 34:3, (349-359), Online publication date: 1-Mar-1974. Loeb H, Rahimtoola S and Gunnar R (1973) The Failing Myocardium: I. Drug Management, Medical Clinics of North America, 10.1016/S0025-7125(16)32310-0, 57:1, (167-185), Online publication date: 1-Jan-1973. Milner R, Chouksey S and Assan R (1973) Metabolic and hormonal effects of glucagon infusion in erythroblastotic infants., Archives of Disease in Childhood, 10.1136/adc.48.11.885, 48:11, (885-891), Online publication date: 1-Nov-1973. Lekven J, Kjekshus J and Mjös O (2009) Effects of Glucagon and Isoproterenol on Severity of Acute Myocardial Ischemic Injury, Scandinavian Journal of Clinical and Laboratory Investigation, 10.3109/00365517309084340, 32:2, (129-137), Online publication date: 1-Jan-1973. Rudolph W and Jehle J (1973) Der Einflu� von Glucagon auf Coronardurchblutung, myokardiale Sauerstoffutilisation und Kohlendioxydproduktion beim MenschenThe effect of glucagon on myocardial blood flow, oxygen consumption and carbon dioxide production in man, Klinische Wochenschrift, 10.1007/BF01483915, 51:3, (108-115), Online publication date: 1-Feb-1973. Berndt T, Ansfield T, Alfonso S and Rowe G (1973) Modification in dogs of the systemic and coronary hemodynamic effects of glucagon by sotalol, American Heart Journal, 10.1016/0002-8703(73)90174-9, 85:5, (671-678), Online publication date: 1-May-1973. K�hn P, Holzhey P, Niederberger M, Fritzsche H, Kroiss A, Brenner B and Kaindl F (1973) Biochemische und h�modynamische Effekte von Zink-Protamin-Glucagon am MenschenBiochemical and haemodynamic effects of zinc-protamin-glucagon in man, Klinische Wochenschrift, 10.1007/BF01468250, 51:19, (951-956), Online publication date: 1-Oct-1973. Tauchert M (1973) Koronarreserve und maximaler Sauerstoffverbrauch des menschlichen Herzens, Basic Research in Cardiology, 10.1007/BF01906424, 68:2, (183-223), Online publication date: 1-Mar-1973. Kones R, Dombeck D and Phillips J (2016) Glucagon in Cardiogenic Shock, Angiology, 10.1177/000331977202300904, 23:9, (525-535), Online publication date: 1-Sep-1972. Nishimura A, Fortner R and Williams J (1972) Effect of glucagon on automaticity, threshold for stimulation, and atrioventricular conduction in patients with impaired impulse formation or conduction, American Heart Journal, 10.1016/0002-8703(72)90368-7, 84:3, (359-365), Online publication date: 1-Sep-1972. Parmley W and Sonnenblick E (1971) Glucagon: A new agent in cardiac therapy, The American Journal of Cardiology, 10.1016/0002-9149(71)90307-9, 27:3, (298-303), Online publication date: 1-Mar-1971. Strauer B (1971) The influence of glucagon on myocardial mechanics of papillary muscles obtained from patients with chronic congestive heart failure, Naunyn-Schmiedebergs Archiv f�r Pharmakologie, 10.1007/BF00997303, 270:1, (90-93), . Einzig S, Todd E, Nicoloff D and Lucas R (1971) Giucagon in Prevention and Abolition of Ouabain-Induced Ventricular Tachycardia in Normokalemic and Hypokalemic Dogs, Circulation Research, 29:1, (88-95), Online publication date: 1-Jul-1971. Diamond G, Forrester J, Danzig R, Parmley W and Swan H (1971) Acute myocardial infarction in man, The American Journal of Cardiology, 10.1016/0002-9149(71)90224-4, 27:6, (612-616), Online publication date: 1-Jun-1971. Fricke G, Simon H and Esser H (1971) Die hämodynamische Wirkung von Glukagon am intakten Hundeherzen, Archiv für Kreislaufforschung, 10.1007/BF02119834, 64:1-2, (98-114), Online publication date: 1-Jan-1971. Kones R and Phillips J (1971) Glucagon in Congestive Heart Failure, Chest, 10.1378/chest.59.4.392, 59:4, (392-397), Online publication date: 1-Apr-1971. Esaulenko A, Moiseeva A, Ivannikov A, Bratischev I and Alidzhanova K (2021) Cardiotoxicity with antihypertensive drugs (literature review) Part 1. Calcium channel blockers and beta-blockers, Medical alphabet, 10.33667/2078-5631-2021-25-12-19:25, (12-19) April 1, 1970Vol 41, Issue 4Article InformationMetrics © 1970 American Heart Association, Inc.https://doi.org/10.1161/01.CIR.41.4.579 Manuscript receivedOctober 27, 1969Manuscript acceptedDecember 2, 1969Originally publishedApril 1, 1970 KeywordsCoronary vascular resistancePressure-time per minuteSecondary coronary vasodilatorCoronary A-V O2 differenceLeft ventricular work133Xe washoutPDF download Advertisement
Referência(s)